 11. Evidence of any clinically relevant disease e.g., renal, hepatic, gastrointestinal, pulmonary, cardiac, or cerebrovascular disease, AIDS, cancer, asthma, neurological or neuromuscular disease, seizure disorder, or clinically significant abnormal laboratory value or any clinical finding that in the judgment of the investigator could potentially be negatively affected by study participation or that could potentially affect study participation 